WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Broker-Dealer
  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Investment Adviser
  • Israel
  • Latin America
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • Decarbonization Strategies
  • Energy Regulation and Competition
  • Project Development and Transactions
  • Project Finance and Tax Equity
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • National Security
  • Payments
  • Privacy and Cybersecurity
  • Strategic Risk and Crisis Management

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Merger Clearance
  • Antitrust Litigation
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • FoodTech and AgTech
  • Fintech and Financial Services
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Semiconductors
  • Software

  • Offices
  • Events
  • Pro Bono
  • Community
  • Our Diversity
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Beijing
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • SOMA
  • Washington, D.C.
  • Wilmington, DE

  • Law Students + Recent Graduates
  • Experienced Attorneys
  • Patent Agents
  • Professional Staff
  • Alternative Legal Careers
  • Contact Recruiting
Lori P. Westin
Partner
Patents and Innovations
San Diego
lwestin@wsgr.com

D858-350-2225

Download vCard
Open PDF

Dr. Lorelei (Lori) Westin is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. Before joining the firm, Lori served as a federal law clerk for the Honorable John A. Houston in the Southern District of California. She also was a patent agent at Howrey Simon Arnold & White. Prior to Howrey, Lori had extensive experience as a research scientist, serving as a senior research scientist in Advanced Technologies at Nanogen, Inc.; a research associate in the Regulatory Biology Laboratory at the Salk Institute; and a postdoctoral fellow in the Laboratory of Molecular Genetics, CMB, at the Karolinska Institute in Sweden. She is the primary author of numerous scientific and legal publications, and is an inventor on seven issued U.S. patents on microchip and DNA amplification technology.

Lori has held numerous fellowships including: Fellow, Centers for Academic Excellence, the Center for Law, Technology and Communications, Highest Honors; J. Aron Foundation Fellow; Karolinska Institute, Stockholm, Sweden, National Science Foundation Minority Postdoctoral Fellow; Fulbright Fellow; and Pre-doctoral Fellow, National Science Foundation.

Experience

Dr. Lorelei (Lori) Westin is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. Before joining the firm, Lori served as a federal law clerk for the Honorable John A. Houston in the Southern District of California. She also was a patent agent at Howrey Simon Arnold & White. Prior to Howrey, Lori had extensive experience as a research scientist, serving as a senior research scientist in Advanced Technologies at Nanogen, Inc.; a research associate in the Regulatory Biology Laboratory at the Salk Institute; and a postdoctoral fellow in the Laboratory of Molecular Genetics, CMB, at the Karolinska Institute in Sweden. She is the primary author of numerous scientific and legal publications, and is an inventor on seven issued U.S. patents on microchip and DNA amplification technology.

Lori has held numerous fellowships including: Fellow, Centers for Academic Excellence, the Center for Law, Technology and Communications, Highest Honors; J. Aron Foundation Fellow; Karolinska Institute, Stockholm, Sweden, National Science Foundation Minority Postdoctoral Fellow; Fulbright Fellow; and Pre-doctoral Fellow, National Science Foundation.

Education
  • J.D., Thomas Jefferson School of Law, 2004Summa Cum Laude; Managing Editor and Editor-in-Chief, Thomas Jefferson Law Review
  • Ph.D., Biology, Boston UniversityBoston University Dean's Fellow, Graduate School of Arts and Sciences
  • M.A., Biology, Boston University
  • B.A., Animal Physiology, University of California, San Diego, 1987UCSD Presidential Fellow and Undergraduate Research (MARC) Fellow
Honors
  • Named to San Diego Business Journal’s “Top Women of Influence in Law” for 2023
  • Recognized by San Diego Business Journal as 2023 “Top Woman of Influence: 50 Over 50”
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office
Credentials
Education
  • J.D., Thomas Jefferson School of Law, 2004Summa Cum Laude; Managing Editor and Editor-in-Chief, Thomas Jefferson Law Review
  • Ph.D., Biology, Boston UniversityBoston University Dean's Fellow, Graduate School of Arts and Sciences
  • M.A., Biology, Boston University
  • B.A., Animal Physiology, University of California, San Diego, 1987UCSD Presidential Fellow and Undergraduate Research (MARC) Fellow
Honors
  • Named to San Diego Business Journal’s “Top Women of Influence in Law” for 2023
  • Recognized by San Diego Business Journal as 2023 “Top Woman of Influence: 50 Over 50”
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author, "Federal Circuit Amgen Case Clarifies Important Aspects of the Biologics Price Competition and Innovation Act," Generic Pharma 2.0, July 22, 2015
  • Co-author with C. Miller, D. Vollmer, R. Radtkey, D. Canter, M. Nerenberg, and J. O'Connell, "Identification of Microorganisms on a Microelectronic Chip Array," Journal of Clinical Microbiology, Vol. 39 at 1097-1104, 2001
  • Co-author with X. Xu, C. Miller, L. Wang, C.F. Edman, and M. Nerenberg, "Anchored Multiplex Amplification on a Microelectronic Chip Array," Nat. Biotechnol., Vol. 18 at 199-204, 2000
  • Co-author with P. Blomquist, J.F. Milligan, and Wrange, "Triple Helix DNA Alters Nucleosomal Histone DNA Interactions and Acts As a Nucleosome Barrier," Nucleic Acids Research, Vol. 23 at 2184-2191, 1995
  • Co-author with L.E. Perez and I.P. Callard, "Regulation of Hepatic Vitellogenin Synthesis in the Little Skate (Raja erinacea) - Use of a Homologous Enzyme-Linked Immunosorbent Assay," Journal of Experimental Zoology, Vol. 266 at 31-39, 1993
  • Co-author with L.E. Perez, "Hormonal Regulation of Hepatic Lipoproteins in Non-Mammalian Vertebrates," Thesis, Department of Biology, Boston University, March, 1992
  • Co-author with L.E. Perez, D. Williams, and I.P. Callard, "Putative Apolipoprotein B-100 in the Freshwater Turtle Chrysemys picta: Effects of Estrogen and Progesterone," Comparative Biochemistry and Physiology, Vol. 103B at 707-713, 1992
  • Co-author with L.E. Perez, M.F. Fenton, and I.P. Callard, "Vitellogenin-Homolog of Mammalian Apolipoproteins?" Comparative Biochemistry and Physiology, Vol. 100B at 821-826, 1991

Select Speaking Engagements

  • Speaker, “Industry Speaker Series: Intellectual Property and Patent Strategies for the Emerging Growth Company,” Keck Graduate Institute, February 2022
Insights

Select Publications

  • Co-author, "Federal Circuit Amgen Case Clarifies Important Aspects of the Biologics Price Competition and Innovation Act," Generic Pharma 2.0, July 22, 2015
  • Co-author with C. Miller, D. Vollmer, R. Radtkey, D. Canter, M. Nerenberg, and J. O'Connell, "Identification of Microorganisms on a Microelectronic Chip Array," Journal of Clinical Microbiology, Vol. 39 at 1097-1104, 2001
  • Co-author with X. Xu, C. Miller, L. Wang, C.F. Edman, and M. Nerenberg, "Anchored Multiplex Amplification on a Microelectronic Chip Array," Nat. Biotechnol., Vol. 18 at 199-204, 2000
  • Co-author with P. Blomquist, J.F. Milligan, and Wrange, "Triple Helix DNA Alters Nucleosomal Histone DNA Interactions and Acts As a Nucleosome Barrier," Nucleic Acids Research, Vol. 23 at 2184-2191, 1995
  • Co-author with L.E. Perez and I.P. Callard, "Regulation of Hepatic Vitellogenin Synthesis in the Little Skate (Raja erinacea) - Use of a Homologous Enzyme-Linked Immunosorbent Assay," Journal of Experimental Zoology, Vol. 266 at 31-39, 1993
  • Co-author with L.E. Perez, "Hormonal Regulation of Hepatic Lipoproteins in Non-Mammalian Vertebrates," Thesis, Department of Biology, Boston University, March, 1992
  • Co-author with L.E. Perez, D. Williams, and I.P. Callard, "Putative Apolipoprotein B-100 in the Freshwater Turtle Chrysemys picta: Effects of Estrogen and Progesterone," Comparative Biochemistry and Physiology, Vol. 103B at 707-713, 1992
  • Co-author with L.E. Perez, M.F. Fenton, and I.P. Callard, "Vitellogenin-Homolog of Mammalian Apolipoproteins?" Comparative Biochemistry and Physiology, Vol. 100B at 821-826, 1991

Select Speaking Engagements

  • Speaker, “Industry Speaker Series: Intellectual Property and Patent Strategies for the Emerging Growth Company,” Keck Graduate Institute, February 2022
Focus Areas
  • Intellectual Property
  • Life Sciences
  • Litigation
  • Patent Litigation
  • Patents and Innovations
  • Post-Grant Review
Recent Insights
Client Highlights
Wilson Sonsini Advises Alpine Immune Sciences on $150 Million Follow-on Public Offering
On November 6, 2023, Alpine Immune Sciences, Inc., a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement. Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the transaction.
Learn More
Client Highlights
Firm Secures Federal Circuit Affirmance of PTAB Victory for Palette Life Sciences
On August 16, 2023, the U.S. Court of Appeals for the Federal Circuit affirmed a Wilson Sonsini Goodrich & Rosati victory for Palette Life Sciences, Inc. against two medical-device patents. Palette provides injectable, biodegradable spacers for protecting non-target organs from radiation treatments. Wilson Sonsini successfully challenged the two broad Incept LLC patents at the Patent Trial and Appeal Board (PTAB) on both anticipation and obviousness grounds. Incept appealed both decisions, challenging the anticipation and obviousness analyses, including arguments on teaching away and commercial success. At the Federal Circuit, Judge Schall (joined by Judge Taranto) affirmed the PTAB’s decisions, with a partial dissent from Judge Newman, who would have remanded some of the claims for further consideration by the PTAB. With this win, more cancer patients will have access to this important protective technology.

Wilson Sonsini partner T.O. Kong argued the case at the PTAB and the Federal Circuit, with support from Tasha Thomas, Lori Westin, Rick Torczon, Kathryn Robinson, and Robyn Moriarty.
Learn More
View All
Recent Events
Speaking Engagements
KGI Industry Speaker Series: Intellectual Property and Patent Strategies for the Emerging Growth Company
Lori Westin possesses a Ph.D. in Biology from Boston University, and a J.D. from the Thomas Jefferson School of Law. Lori has extensive experience that includes serving as a senior research scientist in Advanced Technologies at Nanogen, Inc.; a research associate in the Regulatory Biology Laboratory at the Salk Institute; and a postdoctoral fellow in the Laboratory of Molecular Genetics, CMB, at the Karolinska Institute in Sweden. She is the primary author of numerous scientific and legal publications, and is an inventor on seven issued U.S. patents on microchip and DNA amplification technology. Lori is a Partner at Wilson Sonsini, where she focuses on intellectual property, life sciences, litigation, patent litigation, patents and innovations, and post-grant reviews.
Learn More
WSGR Events
Innovator’s Edge Series: Regulatory Strategies in the Life Sciences
Wilson Sonsini is pleased to present the first of our 2021 Innovator’s Edge Series. Start-ups in the life sciences and biotech sectors, with an urgency to see their products come to market, continue to react to today’s ever-changing business and regulatory landscape. With an abundance of life sciences companies in the spotlight, regulatory strategic planning is more urgent than ever. The stakes are high as companies are faced with the task of navigating regulatory requirements and coordinating regulatory activity with business and patent strategies.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Employee Login
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2023 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.